Healthcare provider profile · identity verified

Haresh Kumar, MD

Allopathic & Osteopathic Physicians|Internal Medicine · GASTONIA, NC · NPI 1528267770

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Haresh Kumar, MD received $15.50 in general payments during 2025 across 1 reported records.

Novo Nordisk Inc accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Ozempic by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Rybelsus by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$15.50

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$15.50	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$15.50	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
Ozempic Normalized: ozempic	Drug	Novo Nordisk Inc	$15.50	1	2025
Source payment records 2025-03-17 · Novo Nordisk Inc · $15.50 · Open Payments source
Rybelsus Normalized: rybelsus	Drug	Novo Nordisk Inc	$15.50	1	2025
Source payment records 2025-03-17 · Novo Nordisk Inc · $15.50 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
Ozempic ozempic	2025	Ozempic	2024	66	exact normalized	Medicare Part D
Rybelsus rybelsus	2025	Rybelsus	2024	47	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Ozempic open payments reported associated product	CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076	Ozempic · 2024 Exact normalized brand match · 1 Part D row	66	22
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Rybelsus open payments reported associated product	CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076	Rybelsus · 2024 Exact normalized brand match · 1 Part D row	47	15

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Rosuvastatin Calcium	Rosuvastatin Calcium	808	255
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	463	193
Metoprolol Succinate	Metoprolol Succinate	461	146
Duloxetine Hcl	Duloxetine Hcl	364	120
Albuterol Sulfate Hfa	Albuterol Sulfate	296	98
Mounjaro	Tirzepatide	291	52
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	247	84
Metformin Hcl	Metformin Hcl	228	85
Allopurinol	Allopurinol	205	70
Omeprazole	Omeprazole	196	77
Prednisone	Prednisone	192	105
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	179	62
Losartan Potassium	Losartan Potassium	156	60
Montelukast Sodium	Montelukast Sodium	155	51
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	140	27
Potassium Chloride	Potassium Chloride	138	53
Diclofenac Sodium	Diclofenac Sodium	134	70
Glipizide	Glipizide	131	40
Tizanidine Hcl	Tizanidine Hcl	129	55
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	127	100
Pantoprazole Sodium	Pantoprazole Sodium	125	47
Trazodone Hcl	Trazodone Hcl	116	39
Naproxen	Naproxen	112	46
Levothyroxine Sodium	Levothyroxine Sodium	109	36
Valsartan	Valsartan	105	44
Tamsulosin Hcl	Tamsulosin Hcl	99	37
Eliquis	Apixaban	98	21
Ciprofloxacin Hcl	Ciprofloxacin Hcl	95	80
Amlodipine Besylate	Amlodipine Besylate	88	46
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	86	34
Fluticasone Propionate	Fluticasone Propionate	85	41
Famotidine	Famotidine	83	33
Buspirone Hcl	Buspirone Hcl	80	26
Donepezil Hcl	Donepezil Hcl	79	28
Triamcinolone Acetonide	Triamcinolone Acetonide	78	58
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	74	20
Furosemide	Furosemide	73	34
Carvedilol	Carvedilol	72	34
Atorvastatin Calcium	Atorvastatin Calcium	71	35
Isosorbide Mononitrate Er	Isosorbide Mononitrate	71	29
Ozempic	Semaglutide	66	22
Jardiance	Empagliflozin	64	27
Torsemide	Torsemide	60	19
Lisinopril	Lisinopril	56	25
Mirtazapine	Mirtazapine	49	16
Clopidogrel	Clopidogrel Bisulfate	48	21
Rybelsus	Semaglutide	47	15
Gabapentin	Gabapentin	46	17
Farxiga	Dapagliflozin Propanediol	45	13
Linzess	Linaclotide	45	18
Ondansetron Odt	Ondansetron	45	26
Alendronate Sodium	Alendronate Sodium	42	19
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	42	15
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	42	13
Hydrochlorothiazide	Hydrochlorothiazide	41	20
Meclizine Hcl	Meclizine Hcl	36	19
Zolpidem Tartrate	Zolpidem Tartrate	36	12
Xarelto	Rivaroxaban	35	14
Azithromycin	Azithromycin	33	16
Doxycycline Hyclate	Doxycycline Hyclate	33	27
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	33	11
Novolin 70-30 Flexpen	Insulin Nph Hum/Reg Insulin Hm	33	11
Tramadol Hcl	Tramadol Hcl	33	21
Vitamin D2	Ergocalciferol (Vitamin D2)	33	16
Alcohol Pads	Alcohol Antiseptic Pads	32	13
Escitalopram Oxalate	Escitalopram Oxalate	32	13
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	32	28
Amitriptyline Hcl	Amitriptyline Hcl	31	13
Glimepiride	Glimepiride	29	11
Lactulose	Lactulose	29	14
Spironolactone	Spironolactone	29	16
Fluconazole	Fluconazole	28	22
Paroxetine Hcl	Paroxetine Hcl	28	suppressed
Promethazine Hcl	Promethazine Hcl	27	13
Levetiracetam	Levetiracetam	26	suppressed
Clonazepam	Clonazepam	25	suppressed
Ipratropium Bromide	Ipratropium Bromide	25	16
Oxybutynin Chloride Er	Oxybutynin Chloride	25	11
Quetiapine Fumarate	Quetiapine Fumarate	25	suppressed
Roflumilast	Roflumilast	25	suppressed
Symbicort	Budesonide/Formoterol Fumarate	25	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	23	suppressed
Warfarin Sodium	Warfarin Sodium	23	suppressed
Memantine Hcl	Memantine Hcl	22	15
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	21	suppressed
Testosterone Cypionate	Testosterone Cypionate	21	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	20	suppressed
Sertraline Hcl	Sertraline Hcl	20	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	19	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	19	suppressed
Biktarvy	Bictegrav/Emtricit/Tenofov Ala	18	suppressed
Neomycin-Polymyxin-Dexameth	Neomycin/Polymyxin B/Dexametha	18	11
Olmesartan Medoxomil	Olmesartan Medoxomil	18	suppressed
Pravastatin Sodium	Pravastatin Sodium	18	suppressed
Valacyclovir	Valacyclovir Hcl	18	suppressed
Clobetasol Propionate	Clobetasol Propionate	17	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	17	suppressed
Ondansetron Hcl	Ondansetron Hcl	17	suppressed
Lidocaine	Lidocaine	16	suppressed
Metformin Hcl Er	Metformin Hcl	16	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	16	suppressed
Latanoprost	Latanoprost	15	11
Levofloxacin	Levofloxacin	15	12
Acyclovir	Acyclovir	14	suppressed
Atenolol	Atenolol	13	suppressed
Baclofen	Baclofen	13	suppressed
Cilostazol	Cilostazol	13	suppressed
Glipizide Er	Glipizide	13	suppressed
Amoxicillin	Amoxicillin	12	11
Hydralazine Hcl	Hydralazine Hcl	12	suppressed
Nitroglycerin	Nitroglycerin	12	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	12	12
Premarin	Estrogens, Conjugated	12	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	12	suppressed
Bumetanide	Bumetanide	11	suppressed
Chlorthalidone	Chlorthalidone	11	suppressed
Estradiol	Estradiol	11	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	11	suppressed
Nystatin	Nystatin	11	suppressed
Ranolazine Er	Ranolazine	11	suppressed
Terbinafine Hcl	Terbinafine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$15.50 · 1 records	Novo Nordisk Inc	Ozempic, Rybelsus	2	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Ozempic play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error